Mounjaro (Tirzepatide) Injection Pen – 7.5 mg

Introduction

The Mounjaro (Tirzepatide) 7.5 mg Injection Pen is a once-weekly treatment for adults with type 2 diabetes. It is usually prescribed after patients complete therapy at 5 mg, offering the next step in achieving tighter blood sugar control and continued weight management. Manufactured by Eli Lilly, Mounjaro is the first dual GIP and GLP-1 receptor agonist, combining two powerful mechanisms to support better metabolic health.

Who Should Use the 7.5 mg Pen?

• Adults with type 2 diabetes mellitus who require stronger glycaemic control.

• Patients who have already tolerated the 2.5 mg starter dose and 5 mg maintenance dose.

• Individuals who benefit from weight reduction as part of diabetes care.

This dose is not intended for initiation. It is a step-up therapy after the body has adjusted to lower strengths.

How Mounjaro 7.5 mg Works

Mounjaro’s active ingredient, tirzepatide, targets two incretin hormones:

• GLP-1 receptor agonist: Boosts insulin secretion, slows digestion, and reduces appetite.

• GIP receptor agonist: Enhances insulin sensitivity and supports fat metabolism.

Together, these actions lower HbA1c levels, reduce weight, and improve overall cardiometabolic health.

Benefits of Mounjaro 7.5 mg

1. Enhanced Glycaemic Control

• Stimulates insulin only when needed.

• Reduces glucagon levels to stabilise blood sugar.

2. Continued Weight Loss Support

• Helps reduce food intake.

• Promotes satiety for longer periods.

3. Cardiovascular and Metabolic Health

• May improve cholesterol profiles.

• Can reduce blood pressure and other risk factors.

4. Weekly Treatment Convenience

Each pen is pre-filled with a single, ready-to-use 7.5 mg dose. Patients inject once weekly, simplifying long-term adherence.

Dosing and Administration

• Initiation phase: 2.5 mg once weekly for 4 weeks.

• Step-up phase: Increase to 5 mg once weekly.

• Ongoing therapy: 7.5 mg once weekly, continued as tolerated.

• Further escalation: 10 mg, 12.5 mg, or 15 mg if needed.

Administration guidelines:

• Subcutaneous injection into the thigh, abdomen, or upper arm.

• Rotate injection sites weekly.

• 1 pen = 1 week’s dose. For a month of therapy, patients need 4 pens.

Possible Side Effects

Common:

• Nausea

• Diarrhoea

• Decreased appetite

• Vomiting

• Constipation

Serious but rare:

• Pancreatitis

• Gallbladder issues

• Kidney complications due to dehydration

• Severe allergic reactions

⚠️ Contraindicated in patients with a history of medullary thyroid carcinoma or MEN 2.

Storage Information

• Store in a refrigerator (2°C–8°C).

• Do not freeze.

• May be stored at room temperature (below 30°C) for up to 21 days.

• Keep in original packaging until ready to use.

Why Choose the 7.5 mg Pen?

• Provides stronger therapeutic benefits than 5 mg.

• Continues progress in weight reduction and blood sugar control.

• Designed for ease of use with prefilled, once-weekly dosing.

• Backed by results from the SURPASS clinical trial program.

Conclusion

The Mounjaro (Tirzepatide) 7.5 mg Injection Pen is a vital step in diabetes care for patients ready to move beyond the 5 mg dose. By harnessing dual incretin action, it delivers more powerful blood sugar reduction, supports sustainable weight loss, and improves overall metabolic health. With once-weekly, easy-to-use pens, Mounjaro 7.5 mg provides a convenient, clinically proven option for advancing type 2 diabetes management.